0000950170-23-041440.txt : 20230810
0000950170-23-041440.hdr.sgml : 20230810
20230810164642
ACCESSION NUMBER: 0000950170-23-041440
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230808
FILED AS OF DATE: 20230810
DATE AS OF CHANGE: 20230810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Graham G. Walmsley
CENTRAL INDEX KEY: 0001777517
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 231160319
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 1650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 1650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2023-08-08
0001744659
Akero Therapeutics, Inc.
AKRO
0001777517
Graham G. Walmsley
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
true
false
false
false
false
Common Stock
2023-08-08
4
P
false
25000
42.0590
A
600000
I
See Footnote
Common Stock
2168
D
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $41.8634 to $42.3525, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
/s/ Jonathan Young, Attorney-in-Fact
2023-08-10